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What is the best cut-off point for screening gestational diabetes
in Turkish women?
Aydın KÖŞÜŞ, Nermin KÖŞÜŞ, Nilgün TURHAN

Aim: To find an optimal threshold level with higher sensitivity and specificity for screening of gestational diabetes
mellitus (GDM) in Turkish pregnant women.
Materials and methods: This was a retrospective study. Screening for GDM was performed in all pregnant women
between 24 and 28 weeks of gestation using the 1 h 50 g glucose challenge test (GCT) with a subsequent 3 h 100 g oral
glucose tolerance test (OGTT) for confirmation if screened positive. The glucose values obtained were analyzed by both
the Carpenter and Coustan (C&C criteria) and National Diabetes Data Group (NDDG) criteria.
Results: There were 808 women meeting the study inclusion criteria. There were 66 (8.1%) women diagnosed with
GDM using the C&C criteria and 45 (5.7%) using the NDDG criteria. The best cut-off point for GCT was 132 mg/dL for
detecting GDM. No diabetes was found below the glucose level of 130 mg/dL.
Conclusion: GCT is suitable for screening of Turkish women, but place of residence as well as race must be taken into
consideration to establish the best cut-off level of GCT, since ethnic and environmental factors may contribute to the
occurrence of GDM.
Key words: Gestational diabetes, glucose challenge test, glucose tolerance test, cut-off

Türk kadınlarında gestasyonel diyabetin taranmasında en uygun kesme noktası
nedir?
Amaç: Gebe Türk kadınlarında gestasyonel diyabetin (GDM) taranmasında en yüksek sensitivite ve spesifisiteye sahip
olan optimal kesme noktasını bulmaktır.
Yöntem ve gereç: Bu çalışma retrospektif olarak yapılmıştır. Tüm gebe kadınlara 24-28 haftalar arasında 1 saatlik 50
gr glukoz deneme testi (GCT), bu testin pozitifliği durumunda da 3 saatlik 100 gr oral glukoz tolerans testi (OGTT)
yapıldı. Elde edilen glukoz değerleri hem Carpenter ve Coustan (C&C) hem de National Diabetes Data Group (NDDG)
kriterlerine göre incelendi.
Bulgular: Çalışma kriterlerine uyan 808 kadın çalışmaya alındı. C&C kriterlerine göre 66 (% 8,1) kadına GDM tanısı
konulurken, NDDG kriterlerine göre 45 (% 5,7) kadın bu tanıyı aldı. GDM tesbitinde en uygun kesme noktası GCT için
132 mg/dL olarak tesbit edildi. GCT sonucu 130 mg/dL altında olan hiçbir hastada GDM izlenmedi.
Sonuç: GCT Türk kadınlarının taranması için uygun bir testtir. Ancak yerleşim yeri ve ırk faktörü de GCT için kesme
noktasının belirlenmesinde dikkate alınmalıdır. Çünkü etnik ve çevresel faktörlerin gestasyonel diyabet gelişimine
katkısı olabilir.
Anahtar sözcükler: Gestasyonel diyabet, glukoz yükleme testi, glukoz tolerans testi, kesme noktası
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Introduction
Gestational diabetes mellitus (GDM) is defined as
any degree of glucose intolerance with onset or first
recognition during pregnancy (1,2). It affects 1.2% to
14.3% of the pregnant population (1,2). Prevalence
rates of GDM varies widely by ethnicity (3,4);
Asians have the highest reported prevalence rates
(4,5). Considering GDM consequences of increased
perinatal and maternal morbidity and mortality, in
addition to long-term complications, its accurate
identification and treatment is very important (6,7).
The American College of Obstetricians and
Gynecologists (ACOG) and the American Diabetes
Association (ADA) have both recommended that all
pregnant women should be screened for GDM (8,9).
While the optimal method of screening remains
controversial, the 50 g 1 h glucose challenge test
(GCT) is performed most commonly in the world.
This is often followed by a 100 g 3 h oral glucose
tolerance test (OGTT) for confirmation, if screened
positive.
The threshold for a positive GCT necessitating
further diagnostic testing remains controversial (810). In the previous studies, authors recommended
the use of a GCT cut-off level of 130-140 mg/dL
for screening of GDM between 24 and 28 weeks of
gestation (11,12). However, in later studies, most of
the cut-off values were different from those in the
previous reports (13,14). These findings may have
been due to the differences in race and nutrition of
the population.
Both the ADA and ACOG have stated that a
glucose threshold value of ≥140 mg/dL identifies 80%
of women with GDM, and the diagnostic accuracy is
further increased to 90% using a cut-off of 130 mg/
dL. No definitive screening threshold was adopted
by the ACOG, who stated that “either threshold is
acceptable” (1,2).
While a higher threshold gives better specificity
and lowers the likelihood of a false-positive test
result, the disadvantage is that a number of women
who may have gestational diabetes will remain
undiagnosed and untreated. In contrast, a lower
threshold yields a higher sensitivity, but more women
will undergo unnecessary diagnostic testing, which
can be expensive, time-consuming, and leads to
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unnecessary intervention. In this study we tried to
find an optimal threshold level with higher sensitivity
and specificity for screening of GDM in Turkish
pregnant women.
Materials and methods
This retrospective study of diagnostic accuracy was
conducted between January 2008 and December
2009 in Fatih University, Faculty of Medicine,
Ankara. Women screened for GDM and who had
given birth at Fatih University were enrolled in the
study. All relevant data including demographic
information, and GCT and OGTT results were
collected for further analysis. Patients with potential
diabetic pregnancy and any systemic disease were
excluded from the study. Criteria for potential
diabetic pregnancy were one or more of the following:
previous history of GDM, including familial history;
previous fetal weight > 4000 g, previous infants with
congenital anomalies; previous unexplained fetal loss;
hypertension; glucosuria by urine strip; and previous
history of diabetic complications, polyhydramnios,
multi-fetal pregnancies, and delivery prior to 24
completed weeks of gestation.
Screening for GDM was performed in all pregnant
women between 24 and 28 weeks of gestation using
the 1 h 50 g GCT in accordance with protocols
recommended by the ADA and the ACOG with
a subsequent 3 h 100 g OGTT for confirmation
if screened positive. A positive result was defined
as plasma glucose of 125 mg/dL or greater. The
threshold was taken as 125 mg/dL in order not to
miss GDM cases that can be seen with the lower GCT
results. The glucose values obtained were analyzed by
both the Carpenter and Coustan (C&C criteria) and
National Diabetes Data Group (NDDG) criteria for
the diagnosis of GDM and IGT (15,16).
An abnormal 3 h OGTT is defined as 2 or more
plasma glucose values that meet or exceed the
standards of C&C criteria (fasting ≥ 95, l h ≥ 180,
2 h ≥ 155, and 3 h ≥ 140 mg/dL) and the NDDG
(fasting ≥ 105, 1 h ≥ 190, 2 h ≥ 165, and 3h ≥ 145
mg/dL). Fasting plasma glucose (FPG) ≥ 140 mg/dL
was considered as showing diabetes and GCT was
omitted. Plasma glucose ≥ 200 mg/dL after GCT were
also accepted as showing diabetes and 3 h OGTT was
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not performed. Treatment was based on the diagnosis
made according to the C&C criteria. Plasma glucose
was determined from a peripheral venous sample by
the hexokinase method (COBAS Integra 800, Roche,
Germany).
Firstly patients with GDM and IGT were seen
by a dietician and received a dietary evaluation and
diet therapy to achieve normoglycemia. Diet therapy
continued if fasting blood sugar (FBS) < 105 mg/dL,
and 2 h postprandial < 140 mg/dL, with home blood
sugar monitoring continued once daily. In women
with glucose values > 200 mg/dL on initial OGTT and
those who recorded FBS > 105 and 2 h postprandial
glucose > 140 for at least 2-3 values while on a dietary
regimen, insulin therapy was commenced.
The statistical analyses were carried out using
SPSS 15.0. Following the entering of patient data
into the computer, all the necessary diagnostic
checks and corrections were performed. Normal
distribution of measurement values as a convenience
was examined graphically and with the Shapiro-Wilk
test. In presenting descriptive statistics, numbers
and percentages were used for categorical variables,
and median (interquartile range [IQR]) and mean
± SD values were used for the data. The groups,
which were formed according to level of glucose
intolerance, were compared to each other by Kruskal
Wallis test and Bonferroni corrected Mann Whitney
test. Spearman correlation analysis was used for
evaluation of the relationship between demographic
variables and GCT results. Chi-square and Fisher’s

exact test were used for comparison of categorical
variables. Receiver–operating characteristics (ROC)
curve analysis was performed to find the optimal
cut-off point. Sensitivity; specificity; the area under
the curve (AUC), which reflects the probability of
correctly identifying patients; positive predictive
value (PPV); and negative predictive value (NPV)
were calculated. Two-tailed P < 0.05 was considered
statistically significant.
Results
There were 808 women meeting the study inclusion
criteria and available for analysis. The characteristics
of the patients in this study were as follows [expressed
as the median (IQR)]: maternal age was 28 (7)
years, gravida 2 (2), parity 1 (2), BMI 26 (5), birth
weight 3300 (300) g, GCT 157.50 (26). Demographic
characteristics according to GCT results are shown
in Table 1. Maternal characteristics associated with
higher GCT categories included age ≥ 35 and
multiparity (P < 0.001, P = 0.002).
There were 66 (8.1%) women diagnosed with
GDM using the ADA criteria and 45 (5.7%) using the
NDDG criteria during the study period. No diabetes
was found below the glucose level of 130 mg/dL.
If 132 mg/dL was taken as the cut-off point only 2
women with GDM were seen below this level.
Of the 12 women with GDM, 4 needed insulin
treatment. The GCT results of all patients requiring
insulin treatment were over 200 mg/dL. Table 2

Table 1. Demographic characteristics and GCT results of groups (median (IQR)).
Normal GCT

FP-GCT

IGT

GDM

P value

Age (year)

28.0 (7.0)

28.5 (7.0)

29.0 (7.0)

28.5 (9.0)

0.612

Gravidity (n)

2.0 (2.0)

2.0 (2.0)

2.0 (3.0)

2.0 (2.0)

0.858

Parity (n)

1.0 (1.0)

1.0 (2.0)

1.0 (2.0)

1.0 (2.0)

0.893

G. age (week)

26.0 (3.0)

26.0 (3.0)

27.0 (3.0)

27.0 (3.0)

0.269

BMI

26.0 (5.0)

25.0 (4.0)

26.0 (5.0)

26.0 (4.0)

0.624

GCT

112.0 (72.0)

143.5 (22.0)

160.0 (21.0)

175.0 (48.0)

<0.001*

3200.0 (400.0)

3200.0 (400.0)

3200.0 (650.0)

3400.0 (350.0)

0.001¶

Birth weight (g)

* difference between control versus other 3 groups, between FP-GCT versus IGT and GDM
¶ difference between GDM versus other 3 groups.
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Table 2. Sensitivity and specificity of various cutoff values of GCT.

Cut-off
(mg/dL)

GDM according to
C&C

GDM according to
NDDG

Sensitivity

Specificity

PPV

NPV

n

%

n

%

(%)

(%)

(%)

(%)

130

66

100,0

45

100,0

100,0

68,5

21,3

100

132

64

97,0

45

100,0

97,4

70,5

22,6

99,6

140

58

87,9

43

95,6

84,8

77,8

25,0

98,6

150

48

72,7

36

80,0

72,7

86,0

30,4

97,2

160

39

59,1

30

66,7

57,6

91,9

37,1

96,2

170

28

42,4

20

44,4

42,4

95,1

43,8

94,9

180

22

33,3

14

31,1

33,3

97,3

52,4

94,3

PPV: Positive predictive value
NPV: Negative predictive value
presenting sensitivity and specificity

1.0

0.8

Sensitivity

shows the sensitivity and specificity of various cut-off
values of GCT. The probability of GDM in patients
with different GCT results is shown in Table 3. The
ROC curve identified the GCT result above 132 mg/
dL as useful for detecting GDM (Figure). At this
cut-off value, the sensitivity, specificity, PPV, and
NPV of GCT were 97.0%, 70.5%, 22.6%, and 99.6%,
respectively [AUC = 0.903 (95% CI: 0.877-0.930; P
< 0.001)]. If 132 was taken as cut-off point to detect
IGT together with GDM, sensitivity and specificity
would be 99.1% and 74.0%, respectively (AUC =
0.921, 95% CI: 0.901-0.941; P < 0.001) (Figure).

0.6

0.4

0.2

Table 3. The probability of GDM in patients with different GCT
results.
GDM (C&C)

GDM (NDDG)

Cut-off value
(mg/dL)

n

(%)

n

(%)

130

66

(21.3)

45

(14.5)

132

64

(22.6)

45

(15.9)

140

58

(25.0)

43

(18.5)

150

48

(30.4)

36

(22.8)

160

39

(37.1)

30

(28.6)

170

28

(43.8)

20

(31.3)

180

22

(52.4)

14

(33.3)
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0.8
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Figure. ROC curve presenting sensitivity and specificity.

Relation between GCT results and demographic
variables were examined by Spearman correlation
analysis. A weak positive correlation was found
between GCT and maternal age, gravida, parity, and
birth weight. There was a positive correlation between
GCT value and 100 g OGTT 0, 1, and 2 h glucose
levels. The relationship between OGTT results and
demographic variables was also examined. A positive
but weak correlation was found between 0, 1, and 2 h
glucose levels and maternal age and BMI. Results of
the correlation analysis are shown in Table 4.

0.077

0.117

Rho

P value

0.005

0.185(**)

0.024

0.150(*)

0.019

0.156(*)

P value

Rho

P value

Rho

P value

Rho

0.205

0.057

Rho

P value

0.428

–0.036

Rho

P value

0.100

0.074

Rho

P value

0.025

0.101(*)

Rho

P value

<0.001

0.130(**)

Rho

P value

<0.001

0.161(**)

Rho

P value

<0.001

0.196(**)

P value

Rho

P value

Rho

0.043

0.134(*)

0.001

0.223(**)

0.002

0.203(**)

0.168

0.092

0.778

–0.013

0.865

0.008

<0.001

0.197(**)

0.663

0.020

<0.001

0.540(**)

<0.001

0.540(**)

<0.001

0.196(**)

Age

** Correlation is significant at the 0.01 level.

100 g 3

100 g 2

100 g 1

100 g 0

Delivery route

Gender

BMI

Birth weight

Parity

Gravida

Age

50 g GCT

50 g GCT

0.573

–0.039

0.914

0.007

0.232

0.083

0.430

–0.055

0.004

–0.130(**)

0.231

0.054

<0.001

0.209(**)

0.172

0.062

<0.001

0.876(**)

<0.001

0.540(**)

<0.001

0.130(**)

Parity

0.431

–0.070

0.557

0.052

0.235

0.106

0.374

–0.079

0.448

0.034

0.483

–0.032

<0.001

0.159(**)

0.172

0.062

0.310

0.046

0.663

0.020

0.025

0.101(*)

Birth
weight
BMI

0.298

0.092

0.013

0.215(*)

<0.001

0.329(**)

0.635

–0.042

0.857

0.008

0.377

–0.040

<0.001

0.159(**)

<0.001

0.209(**)

<0.001

0.184(**)

<0.001

0.197(**)

0.100

0.074

* Correlation is significant at the 0.05 level.

0.462

–0.051

0.857

–0.012

0.958

–0.004

0.279

–0.075

0.020

–0.105(*)

0.833

0.009

<0.001

0.184(**)

0.310

0.046

<0.001

0.876(**)

<0.001

0.540(**)

<0.001

0.161(**)

Gravida

0.385

–0.077

0.711

–0.033

0.889

0.012

0.458

–0.066

0.965

0.002

0.377

–0.040

0.483

–0.032

0.231

0.054

0.833

0.009

0.865

0.008

0.428

0.036

Gender

0.111

–0.140

0.258

–0.100

0.286

–0.094

0.387

0.076

0.965

0.002

0.857

0.008

0.448

0.034

0.004

–0.130(**)

0.020

–0.105(*)

0.778

–0.013

0.205

0.057

Delivery
route

0.387

0.076

0.458

–0.066

0.635

–0.042

0.374

–0.079

0.430

–0.055

0.279

–0.075

0.168

0.092

0.019

0.156(*)

100 g 0

<0.001

0.310(**)

<.001

0.358(**)

<0.001

0.311(**)

Table 4. Correlation analysis between GCT results and demographic variables.

<0.001

0.287(**)

<0.001

0.635(**)

<0.001

0.311(**)

0.286

–0.094

0.889

0.012

<0.001

0.329(**)

0.235

0.106

0.232

0.083

0.958

–0.004

0.002

0.203(**)

0.024

0.150(*)

100 g 1

<0.001

0.515(**)

<0.001

0.635(**)

<0.001

0.358(**)

0.258

–0.100

0.711

–0.033

0.013

0.215(*)

0.557

0.052

0.914

0.007

0.857

–0.012

0.001

0.223(**)

0.005

0.185(**)

100 g 2

<0.001

0.515(**)

<0.001

0.287(**)

<0.001

0.310(**)

0.111

–0.140

0.385

–0.077

0.298

0.092

0.431

–0.070

0.573

–0.039

0.462

–0.051

0.043

0.134(*)

0.077

0.117

100 g 3
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Discussion
There is a general consensus that the prevalence of
GDM is increasing globally. The prevalence of GDM
is reported to be 1.2% to 14.3% in the literature (1,2).
Several studies have documented increasing trends
in the prevalence from 2% in 1982 (17) and 7.62%
in 1991 (18) to 16.55% in 2001 (19). A recent survey
reported the prevalence of IGT in the age groups of
20-29 years and 30-39 years as 12.2% and 15.3%,
respectively (20). The reasons for this increase and
difference in prevalence rates in different populations
are not known very well.
Ethnicity is one cause. The prevalence of GDM
varies widely with ethnicity (3,4). Asians have the
highest reported prevalence rates of GDM (4,5).
On the other hand, environmental factors also may
modify the condition. Asian immigrants in the
United Kingdom, the United States, and Canada
were investigated in previous studies on racial
variations in the incidence of GDM (21-23). As a
result, they found that environmental factors such as
diet in Western countries may contribute to the high
prevalence of GDM in Asian immigrants. Fujimoto
et al. (24) have shown that environmental factors
may play an important role in the development of
type 2 diabetes since the prevalence of type 2 diabetes
is about 2-fold higher in Japanese Americans than in
native Japanese. Our own data show a prevalence of
GDM of 8.1% if the diagnosis is based on the C&C
criteria.
Numerous screening and diagnostic procedures
such as glycosuria, random, and fasting plasma
glucose to identify cases of GDM are employed
worldwide (1,25), but there is no consensus as yet
regarding the best screening method, with most
centers using the ADA and the ACOG guidelines,
which recommend screening with the 50 g GCT,
followed by a 3 h 100 g OGTT in women who screen
positive, while in the UK the 75 g load is favored, and
this is also recommended by the WHO.
Finally, even after the diagnostic test is conducted,
there is controversy regarding the diagnostic criteria.
Because of perceived low sensitivities with the NDDG
criteria, the ADA recommended that the C&C
criteria should replace the NDDG. However, both are
528

still in use, while in the UK the WHO recommended
criteria following a 75 g OGTT are mostly used (26).
A cut-off value between 130 and 140 mg/dL
is commonly used for performing the diagnostic
OGTT in the clinical settings. To date, most studies
that have examined the screening threshold of GCT
have focused on the sensitivity and specificity of
different GCT thresholds. Several authors evaluated
the sensitivity and specificity to determine the
cut-off value in different populations (27,28). In
most studies, the authors recommended the use of
GCT level at 130-140 mg/dL for GDM screening
in potential diabetic pregnancy between 24 and 28
weeks of gestation (11,12). However, in some studies
considerably lower or higher thresholds for GCT
are advised. For example, while Vitoratos et al. (13)
recommended 126 mg/dL as the optimal threshold,
Punthumapol et al. (29) recommended 177 mg/
dL and Tanir et al. (14) recommended 185 mg/dL.
These findings may be due to the differences in race
and nutrition of the populations. The sensitivity and
specificity of these cut-off values were 50%-78.33%
and 65.75%-86.79%, respectively. The PPVs were
26.72%-33.96%. Although the PPVs were low, the
NPVs were high, i.e. 92.73%-94.82%, that meant low
false negative. Low PPVs were not a problem, because
GCT is a screening test and must be confirmed by
OGTT for exact diagnosis of GDM.
Racial differences regarding the glucose screening
test findings have been demonstrated. Nahum and
Huffaker (30) suggested race-specific criteria for GCT
because of the heterogeneity of glucose intolerance
between ethnic groups. In the study by Eslamian
and Ramezani (31), for GCT, a sensitivity of 91.7%,
specificity of 83.6%, PPV of 34.4%, and NPV of
99.1% with a cut-off value of 135 mg/dL were found.
In the study of Miyakoshi et al., based on receiver
operating characteristic curve (ROC), they identified
a GCT finding above 140 mg/dL as the cut-off value
for detecting GDM, which showed a sensitivity and
specificity of 96% and 76%, respectively (12).
In Turkey, Korucuoglu et al. (32) suggested that
50 g GCT as a diagnostic test is time-consuming,
uncomfortable, and expensive and can be omitted
up to a cut-off value of 147.5 mg/dL, especially for
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those patients with no risk factors. On the other
hand, a GCT value of 180 mg/dL or higher proves
that a further diagnostic test is unnecessary as these
patients are associated with unfavorable perinatal
and fetal outcomes. They thought that this combined
approach would improve maternal-fetal outcomes
together with a decrease in unnecessary diagnostic
tests.
Recently, the Hyperglycemia and Adverse
Pregnancy Outcomes (HAPO) study (33), which
was a large-scale multinational epidemiologic study
including 25,000 pregnant women, demonstrated
that risk of adverse maternal, fetal, and neonatal
outcomes continuously increased as a function
of maternal glycemia at 24-28 weeks, even within
ranges previously considered normal for pregnancy.
These results have led to careful reconsideration of
the diagnostic criteria for GDM and nowadays the
International Association of Diabetes and Pregnancy
Study Groups (IADPSG), an international consensus
group with representatives from multiple obstetrical
and diabetes organizations, including ADA, has
recommended new diagnostic criteria for GDM (34).
According to the statement of IADPSG, 75 g OGTT
at 24-28 weeks of gestation was recommended with
cut-off values of 5.1 mmol/L (≥92 mg/dL) for fasting
plasma glucose (FPG), 10.0 mmol/L (≥180 mg/
dL) for 1 h, and 8.5 mmol/L (≥153 mg/dL) for 2 h
plasma glucose. Because only one abnormal value is
sufficient to make the diagnosis, these new criteria
will significantly increase the prevalence of GDM.
In addition, there are few data regarding therapeutic
interventions in women who will now be diagnosed
with GDM based on only one blood glucose value
above the specified cut-off points but fall in the
normal category according to the older criterion that
needs at least 2 abnormal values for diagnosis.
A few months ago, the 6th International
Symposium on Diabetes and Pregnancy was held in
Salzburg, Austria. It was stated in the symposium that
the risk of adverse pregnancy outcomes in women
with fasting plasma glucose (FPG) near to the cutoff value (FPG < 92) is not increased, indicating
that the new criteria may lead to overdiagnosis.
Similarly, there was a poor correlation between FPG

and OGTT values. Therfore, it was stated that the
new IADPSG criteria were “not evidence-based” and
need modification (35,36). Additional well-designed
clinical studies are needed to determine the optimal
method and optimal threshold levels with higher
sensitivity and specificity for screening of GDM.
In the present study, we used an ROC curve to
find the best cut-off point. A cut-off value of 132 mg/
dL yielded a sensitivity of 97.4% and a specificity of
70.5% for GDM. The proportion of gravidas exceeding
132 mg/dL was found to be 35% of all subjects, and
22.6% of women with a positive screening test were
diagnosed with GDM.
An improvement of sensitivity from 84.8% for a
threshold of 140 mg/dL to 97.4% for a threshold of
132 mg/dL has been demonstrated, with an increased
screen positive rate and the performance of diagnostic
OGTTs rising from 28.7% to 35.0%. Thus, if women
with a GCT between 130 and 139 mg/dL remain at
risk for due to hyperglycemia or undiagnosed GDM,
then a threshold of 140 mg/dL may not adequately
capture those at risk. Indeed, our study shows that
women with a GCT between 130 and 139 mg/dL are
at risk for GDM. Of note, the percentage of women
in our cohort whose GCT values were 140 mg/dL or
higher was 28.7%, and the percentage with plasma
glucose of 132 mg/dL or higher was 35.0%, which
were higher than those reported by Coustan et al.
in 1998 (37). The reason for the higher rate may be
ethnic and environmental differences and increased
obesity in the Turkish population.
In conclusion, we recommend GCT as an
international screening method. It is also suitable for
Turkish women. The place of residence as well as race
need be taken into consideration to establish the best
cut-off level of GCT, since ethnic and environmental
factors may contribute to the occurrence of
GDM. Furthermore, with the C&C criteria, the
highest sensitivity is achieved by using the glucose
challenge test threshold of 130 mg/dL in the Turkish
population. Because of the fact that failure to identify
and treat GDM may result in an increase in perinatal
and maternal morbidity and mortality, in addition
to long-term complications, we think that a glucose
challenge test threshold of 130 mg/dL should be
considered a positive screening result.
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